Image 1_Using sodium glycodeoxycholate to develop a temporary infant-like gut barrier model, in vitro.pdf حسب Francesca Bietto (21511316)

Table 1_Using sodium glycodeoxycholate to develop a temporary infant-like gut barrier model, in vitro.docx حسب Francesca Bietto (21511316)

Image 5_Using sodium glycodeoxycholate to develop a temporary infant-like gut barrier model, in vitro.pdf حسب Francesca Bietto (21511316)

Image 4_Using sodium glycodeoxycholate to develop a temporary infant-like gut barrier model, in vitro.pdf حسب Francesca Bietto (21511316)

Image 2_Using sodium glycodeoxycholate to develop a temporary infant-like gut barrier model, in vitro.pdf حسب Francesca Bietto (21511316)

Image 3_Using sodium glycodeoxycholate to develop a temporary infant-like gut barrier model, in vitro.pdf حسب Francesca Bietto (21511316)

RTL8 incorporates into PEG10 VLPs and decreases the efficiency of release. حسب Will Campodonico (20485651)

HSP90 inhibition by RGRN-305 and 17-AAG decreased proinflammatory protein secretion. حسب Hakim Ben Abdallah (14578241)

DataSheet1_Decreasing viscosity and increasing accessible load by replacing classical diluents with a hydrotrope in liquid–liquid extraction.docx حسب Asmae El Maangar (19690522)

CS rates increased with protraction and decreased with retraction. حسب Paul Hage (21071783)

Aripiprazole significantly decreases phosphorylated Src (Y416) levels in dHL-60 cells. حسب Courtney A. Swain (15170264)

Histogram of number of drugs with (a) increased and (b) decreased usage within 12 months. حسب Nguyen Thach (20347852)

In vivo combination activity of AMG 510 and pemigatinib in epithelial-like or mesenchymal-like phenotype lung cancer PDX models. حسب Angela Abdollahi (15166230)

MigC interacts with and decreases the activity of MurD. حسب Jeanette M. Critchlow (21553796)

Maximum IFN concentrations are decreased in severe patients. حسب Sonia T. Gazeau (21512764)

Data Sheet 1_Validation of an MPS-based intestinal cell culture model for the evaluation of drug-induced toxicity.docx حسب Stefanie Hoffmann (3756733)

"…Overall, from the 23 tested compounds, 15 showed the expected outcome, i.e., the compound led to a decrease of the TEER for the positive control compounds, or the TEER value remained stable after treatment with non-GI-toxic compounds.…"

Table_3_Loss of CDYL Results in Suppression of CTNNB1 and Decreased Endometrial Receptivity.docx حسب Xiaowei Zhou (1332225)

"…In the present study, we demonstrated that chromodomain Y like (CDYL) was highly expressed in the endometrium at mid-secretory phase during the normal menstrual cycles. …"

Image_4_Loss of CDYL Results in Suppression of CTNNB1 and Decreased Endometrial Receptivity.TIF حسب Xiaowei Zhou (1332225)

"…In the present study, we demonstrated that chromodomain Y like (CDYL) was highly expressed in the endometrium at mid-secretory phase during the normal menstrual cycles. …"

Image_1_Loss of CDYL Results in Suppression of CTNNB1 and Decreased Endometrial Receptivity.TIF حسب Xiaowei Zhou (1332225)

"…In the present study, we demonstrated that chromodomain Y like (CDYL) was highly expressed in the endometrium at mid-secretory phase during the normal menstrual cycles. …"

Image_3_Loss of CDYL Results in Suppression of CTNNB1 and Decreased Endometrial Receptivity.TIF حسب Xiaowei Zhou (1332225)

"…In the present study, we demonstrated that chromodomain Y like (CDYL) was highly expressed in the endometrium at mid-secretory phase during the normal menstrual cycles. …"